Cargando…

A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors

BACKGROUND: The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. MATERIAL AND METHODS: This 5-year retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Manfredi, Maddalena, Mergoni, Giovanni, Goldoni, Matteo, Salvagni, Stefania, Merigo, Elisabetta, Meleti, Marco, Vescovi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medicina Oral S.L. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432112/
https://www.ncbi.nlm.nih.gov/pubmed/28390132
http://dx.doi.org/10.4317/medoral.21728
_version_ 1783236573917085696
author Manfredi, Maddalena
Mergoni, Giovanni
Goldoni, Matteo
Salvagni, Stefania
Merigo, Elisabetta
Meleti, Marco
Vescovi, Paolo
author_facet Manfredi, Maddalena
Mergoni, Giovanni
Goldoni, Matteo
Salvagni, Stefania
Merigo, Elisabetta
Meleti, Marco
Vescovi, Paolo
author_sort Manfredi, Maddalena
collection PubMed
description BACKGROUND: The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. MATERIAL AND METHODS: This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms. RESULTS: Of the 156 patients enrolled in the study, 17 developed ONJ (10.89%). At the multivariate analysis, severe periodontal disease (P=0.025), tooth extraction (P<0.0001) and starting the preventive dental program after the beginning of ZA therapy (P=0.02) were the only factors which showed a significant association with the occurrence of ONJ. CONCLUSIONS: This study demonstrated the importance of beginning dental prevention before zoledronic acid exposure in reducing ONJ occurrence, especially in the long term. The results of this research show that control of periodontal disease and an increase in the time between tooth extraction and the first ZA administration are recommended in order to reduce the risk of ONJ development. Key words:Osteonecrosis of the jaw, dental prevention, zoledronic acid, incidence.
format Online
Article
Text
id pubmed-5432112
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medicina Oral S.L.
record_format MEDLINE/PubMed
spelling pubmed-54321122017-05-18 A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors Manfredi, Maddalena Mergoni, Giovanni Goldoni, Matteo Salvagni, Stefania Merigo, Elisabetta Meleti, Marco Vescovi, Paolo Med Oral Patol Oral Cir Bucal Research BACKGROUND: The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. MATERIAL AND METHODS: This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms. RESULTS: Of the 156 patients enrolled in the study, 17 developed ONJ (10.89%). At the multivariate analysis, severe periodontal disease (P=0.025), tooth extraction (P<0.0001) and starting the preventive dental program after the beginning of ZA therapy (P=0.02) were the only factors which showed a significant association with the occurrence of ONJ. CONCLUSIONS: This study demonstrated the importance of beginning dental prevention before zoledronic acid exposure in reducing ONJ occurrence, especially in the long term. The results of this research show that control of periodontal disease and an increase in the time between tooth extraction and the first ZA administration are recommended in order to reduce the risk of ONJ development. Key words:Osteonecrosis of the jaw, dental prevention, zoledronic acid, incidence. Medicina Oral S.L. 2017-05 2017-04-08 /pmc/articles/PMC5432112/ /pubmed/28390132 http://dx.doi.org/10.4317/medoral.21728 Text en Copyright: © 2017 Medicina Oral S.L. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Manfredi, Maddalena
Mergoni, Giovanni
Goldoni, Matteo
Salvagni, Stefania
Merigo, Elisabetta
Meleti, Marco
Vescovi, Paolo
A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors
title A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors
title_full A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors
title_fullStr A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors
title_full_unstemmed A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors
title_short A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors
title_sort 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432112/
https://www.ncbi.nlm.nih.gov/pubmed/28390132
http://dx.doi.org/10.4317/medoral.21728
work_keys_str_mv AT manfredimaddalena a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT mergonigiovanni a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT goldonimatteo a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT salvagnistefania a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT merigoelisabetta a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT meletimarco a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT vescovipaolo a5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT manfredimaddalena 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT mergonigiovanni 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT goldonimatteo 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT salvagnistefania 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT merigoelisabetta 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT meletimarco 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors
AT vescovipaolo 5yearretrospectivelongitudinalstudyontheincidenceandtheriskfactorsofosteonecrosisofthejawsinpatientstreatedwithzoledronicacidforbonemetastasesfromsolidtumors